Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2854732 | 0.78 | HTT (0.49) | HTTALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL13554245 | 0.76 | ENPP2 (0.33) | HTT | |
| SCHEMBL981866 | 0.75 | CYP3A4 (0.39) | SLC6A4HTTTDP1L3MBTL1MAPT | |
| SCHEMBL1091776 | 0.75 | HPGD (0.51) | HTTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14954870 | 0.74 | SLC5A2 (0.39) | SLC6A4CCR5 | |
| SCHEMBL15057756 | 0.74 | AAK1 (0.42) | AAK1ALDH1A1MAPK1TDP1L3MBTL1 | |
| SCHEMBL427426 | 0.74 | KDR (0.40) | SLC6A4CCR5TDP1L3MBTL1 | |
| SCHEMBL23364707 | 0.73 | AAK1 (0.38) | SLC6A4AAK1HTTALDH1A1MAPK1 | |
| SCHEMBL29932935 | 0.73 | AAK1 (0.38) | SLC6A4AAK1HTTALDH1A1MAPK1 | |
| SCHEMBL4311584 | 0.73 | HTR2A (0.39) | SLC6A4RAB9ASMN1; SMN2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | SLC6A4 165/4885AAK1 2180/4885HTT 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.